Curated News
By: NewsRamp Editorial Staff
July 24, 2026
NanoViricides Raises $3.8M for Broad-Spectrum Antiviral Drug Development
TLDR
- NanoViricides raised $3.8M via a direct offering, giving investors a chance to buy at $1.75 per warrant.
- NanoViricides sold 2.5M shares and warrants to an institutional investor, with closings expected by July 27, 2026.
- NanoViricides advances broad-spectrum antiviral drugs like NV-387, aiming to treat COVID, RSV, and other viral diseases.
- NanoViricides' NV-387 is a nanomaterial drug candidate that may work against multiple viruses including Measles and Ebola.
Impact - Why it Matters
This news matters because NanoViricides is advancing NV-387, a broad-spectrum antiviral that could address multiple viral threats including COVID-19, RSV, Influenza, and MPOX. The $3.8 million funding will support its progression into Phase II clinical trials, potentially leading to more effective treatments for respiratory infections. For investors, it signals continued financial backing and progress in the antiviral pipeline, which could have significant implications for public health and the biotech sector.
Summary
NanoViricides, Inc. (NYSE American: NNVC) has announced a registered direct offering expected to generate approximately $3.8 million in gross proceeds. The company entered into a securities purchase agreement with a single fundamental institutional investor for the sale of 2,516,339 common shares or pre-funded warrants, along with warrants to purchase an equal number of common shares at an exercise price of $1.75 per share. D. Boral Capital LLC is serving as exclusive placement agent for the offering, which is anticipated to close on or about July 27, 2026. This capital infusion comes as NanoViricides advances its lead drug candidate NV-387, a broad-spectrum antiviral, toward Phase II human clinical trials for respiratory viral infections including RSV, COVID, Long COVID, Influenza, and MPOX.
NanoViricides is a clinical-stage company developing special purpose nanomaterials for antiviral therapy, based on the nanoviricide(TM) technology licensed from TheraCour Pharma, Inc. The company's pipeline includes NV-387 (API NV-CoV-2) for COVID-19 and NV-CoV-2-R, which encapsulates remdesivir (developed by Gilead) within polymeric micelles. The company believes the remdesivir-encapsulated candidate may be more easily approvable given remdesivir's existing FDA approval. Additionally, NanoViricides is developing drugs for numerous viral diseases such as oral and genital herpes, eye viruses, influenza strains, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola. The company holds exclusive perpetual licenses for several antiviral drug technologies targeting specific viruses, with plans to expand into RSV, poxviruses, and enteroviruses pending research success.
Investors can find the latest updates on NNVC in the company's newsroom. The news release was distributed by NetworkNewsWire (NNW), a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which offers press release distribution via InvestorWire, editorial syndication to over 5,000 outlets, and social media distribution to millions of followers. For more information, visit www.NetworkNewsWire.com or contact their Austin, Texas office.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Raises $3.8M for Broad-Spectrum Antiviral Drug Development
